908 research outputs found
Subcellular organization of UBE3A in human cerebral cortex.
BackgroundLoss of UBE3A causes Angelman syndrome, whereas excess UBE3A activity appears to increase the risk for autism. Despite this powerful association with neurodevelopmental disorders, there is still much to be learned about UBE3A, including its cellular and subcellular organization in the human brain. The issue is important, since UBE3A's localization is integral to its function.MethodsWe used light and electron microscopic immunohistochemistry to study the cellular and subcellular distribution of UBE3A in the adult human cerebral cortex. Experiments were performed on multiple tissue sources, but our results focused on optimally preserved material, using surgically resected human temporal cortex of high ultrastructural quality from nine individuals.ResultsWe demonstrate that UBE3A is expressed in both glutamatergic and GABAergic neurons, and to a lesser extent in glial cells. We find that UBE3A in neurons has a non-uniform subcellular distribution. In somata, UBE3A preferentially concentrates in euchromatin-rich domains within the nucleus. Electron microscopy reveals that labeling concentrates in the head and neck of dendritic spines and is excluded from the PSD. Strongest labeling within the neuropil was found in axon terminals.ConclusionsBy highlighting the subcellular compartments in which UBE3A is likely to function in the human neocortex, our data provide insight into the diverse functional capacities of this E3 ligase. These anatomical data may help to elucidate the role of UBE3A in Angelman syndrome and autism spectrum disorder
Treatment of Epithelioid Sarcoma at the Royal Marsden Hospital
Purpose: The aim of this study was to assess treatment and outcome with respect to clinical and pathological features
Horizontal force production and multi-segment foot kinematics during the acceleration phase of bend sprinting
This paper investigated horizontal force production, foot kinematics and metatarsophalangeal (MTP) joint push-off axis use during acceleration in bend (anti-clockwise) and straight-line sprinting. It was hypothesised that bend sprinting would cause the left step push-off to occur about the oblique axis, resulting in a decrease in propulsive force. Three-dimensional kinematic and ground reaction force data were collected from nine participants during sprinting on the bend (36.5 m radius) and straight. Anteroposterior force was reduced at 38-44% of stance during bend sprinting compared with the straight. This coincided with an increase in mediolateral force for the majority of the stance phase (3-96%) on the bend compared with the straight. In addition, a lower propulsive impulse was reported on the bend compared with the straight. Analysis of multi-segment foot kinematics provides insight into the possible mechanisms behind these changes in force production. Mean mediolateral centre of pressure position was more lateral in relation to the second metatarsal head in the left step on the bend compared with the straight, indicating the oblique axis was used for push-off at the MTP joint. Greater peak joint angles of the left foot were also reported, in particular, an increase in left step midfoot eversion and internal ankle rotation. It is possible these changes in joint kinematics are associated with the observed decrease in propulsive force. Therefore, practitioners should seek to strengthen muscles such as tibialis posterior in frontal and sagittal planes and ensure specificity of training which may aid in addressing these force reductions
TL1A/DR3 axis involvement in the inflammatory cytokine network during pulmonary sarcoidosis
BACKGROUND:
TNF-like ligand 1A (TL1A), a recently recognized member of the TNF superfamily, and its death domain receptor 3 (DR3), firstly identified for their relevant role in T lymphocyte homeostasis, are now well-known mediators of several immune-inflammatory diseases, ranging from rheumatoid arthritis to inflammatory bowel diseases to psoriasis, whereas no data are available on their involvement in sarcoidosis, a multisystemic granulomatous disease where a deregulated T helper (Th)1/Th17 response takes place.
METHODS:
In this study, by flow cytometry, real-time PCR, confocal microscopy and immunohistochemistry analyses, TL1A and DR3 were investigated in the pulmonary cells and the peripheral blood of 43 patients affected by sarcoidosis in different phases of the disease (29 patients with active sarcoidosis, 14 with the inactive form) and in 8 control subjects.
RESULTS:
Our results demonstrated a significant higher expression, both at protein and mRNA levels, of TL1A and DR3 in pulmonary T cells and alveolar macrophages of patients with active sarcoidosis as compared to patients with the inactive form of the disease and to controls. In patients with sarcoidosis TL1A was strongly more expressed in the lung than the blood, i.e., at the site of the involved organ. Additionally, zymography assays showed that TL1A is able to increase the production of matrix metalloproteinase 9 by sarcoid alveolar macrophages characterized, in patients with the active form of the disease, by reduced mRNA levels of the tissue inhibitor of metalloproteinase (TIMP)-1.
CONCLUSIONS:
These data suggest that TL1A/DR3 interactions are part of the extended and complex immune-inflammatory network that characterizes sarcoidosis during its active phase and may contribute to the pathogenesis and to the progression of the disease
Synthesis and Quantitative Structure–Activity Relationship of Imidazotetrazine Prodrugs with Activity Independent of O6-Methylguanine-DNA-methyltransferase, DNA Mismatch Repair and p53.
The antitumor prodrug Temozolomide is compromised by its dependence for activity on DNA mismatch repair (MMR) and the repair of the chemosensitive DNA lesion, O6-methylguanine (O6-MeG), by O6-methylguanine-DNA-methyltransferase (EC 2.1.1.63, MGMT). Tumor response is also dependent on wild-type p53. Novel 3-(2-anilinoethyl)-substituted imidazotetrazines are reported that have activity independent of MGMT, MMR and p53. This is achieved through a switch of mechanism so that bioactivity derives from imidazotetrazine-generated arylaziridinium ions that principally modify guanine-N7 sites on DNA. Mono- and bi-functional analogs are reported and a quantitative structure-activity relationship (QSAR) study identified the p-tolyl-substituted bi-functional congener as optimized for potency, MGMT-independence and MMR-independence. NCI60 data show the tumor cell response is distinct from other imidazotetrazines and DNA-guanine-N7 active agents such as nitrogen mustards and cisplatin. The new imidazotetrazine compounds are promising agents for further development and their improved in vitro activity validates the principles on which they were designed
Subcellular organization of UBE3A in human cerebral cortex
Abstract
Background
Loss of UBE3A causes Angelman syndrome, whereas excess UBE3A activity appears to increase the risk for autism. Despite this powerful association with neurodevelopmental disorders, there is still much to be learned about UBE3A, including its cellular and subcellular organization in the human brain. The issue is important, since UBE3A’s localization is integral to its function.
Methods
We used light and electron microscopic immunohistochemistry to study the cellular and subcellular distribution of UBE3A in the adult human cerebral cortex. Experiments were performed on multiple tissue sources, but our results focused on optimally preserved material, using surgically resected human temporal cortex of high ultrastructural quality from nine individuals.
Results
We demonstrate that UBE3A is expressed in both glutamatergic and GABAergic neurons, and to a lesser extent in glial cells. We find that UBE3A in neurons has a non-uniform subcellular distribution. In somata, UBE3A preferentially concentrates in euchromatin-rich domains within the nucleus. Electron microscopy reveals that labeling concentrates in the head and neck of dendritic spines and is excluded from the PSD. Strongest labeling within the neuropil was found in axon terminals.
Conclusions
By highlighting the subcellular compartments in which UBE3A is likely to function in the human neocortex, our data provide insight into the diverse functional capacities of this E3 ligase. These anatomical data may help to elucidate the role of UBE3A in Angelman syndrome and autism spectrum disorder
Adipocyte-specific protein tyrosine phosphatase 1B deletion increases lipogenesis, adipocyte cell size and is a minor regulator of glucose homeostasis
Peer reviewedPublisher PD
The Large Enriched Germanium Experiment for Neutrinoless Double Beta Decay (LEGEND)
The observation of neutrinoless double-beta decay (0)
would show that lepton number is violated, reveal that neutrinos are Majorana
particles, and provide information on neutrino mass. A discovery-capable
experiment covering the inverted ordering region, with effective Majorana
neutrino masses of 15 - 50 meV, will require a tonne-scale experiment with
excellent energy resolution and extremely low backgrounds, at the level of
0.1 count /(FWHMtyr) in the region of the signal. The
current generation Ge experiments GERDA and the MAJORANA DEMONSTRATOR
utilizing high purity Germanium detectors with an intrinsic energy resolution
of 0.12%, have achieved the lowest backgrounds by over an order of magnitude in
the 0 signal region of all 0
experiments. Building on this success, the LEGEND collaboration has been formed
to pursue a tonne-scale Ge experiment. The collaboration aims to develop
a phased 0 experimental program with discovery potential
at a half-life approaching or at years, using existing resources as
appropriate to expedite physics results.Comment: Proceedings of the MEDEX'17 meeting (Prague, May 29 - June 2, 2017
- …